Trexquant Investment LP Invests $5.17 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Trexquant Investment LP purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,891 shares of the biopharmaceutical company’s stock, valued at approximately $5,174,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of REGN. Annis Gardner Whiting Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at about $26,000. Fortitude Family Office LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $31,000. MCF Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares during the last quarter. Criterion Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $37,000. Finally, Sutton Wealth Advisors Inc. raised its stake in shares of Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.0 %

REGN opened at $983.80 on Thursday. The firm has a market cap of $108.40 billion, a P/E ratio of 29.06, a P/E/G ratio of 2.05 and a beta of 0.17. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $998.33. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The business has a fifty day simple moving average of $943.97 and a 200-day simple moving average of $912.75.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of the stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $979.23, for a total value of $22,355,820.90. Following the sale, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Leonard S. Schleifer sold 22,830 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 17th. The shares were sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the completion of the sale, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bonnie L. Bassler sold 854 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $979.25, for a total value of $836,279.50. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,353,323.50. The disclosure for this sale can be found here. Insiders sold a total of 54,925 shares of company stock worth $53,649,186 over the last 90 days. Corporate insiders own 8.83% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price on the stock. Evercore ISI started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target on the stock. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Truist Financial restated a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $989.36.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.